Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal Spray
November 15, 2021 07:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma" or "the Company") a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021
November 09, 2021 07:01 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Reports Third Quarter 2021 Financial Results and Recent Business Highlights
November 04, 2021 16:05 ET
|
Oyster Point Pharma, Inc.
FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021Field Force Onboarding Completed During Q3’21, U.S. Launch...
Oyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of The Signs and Symptoms of Dry Eye Disease
November 04, 2021 08:00 ET
|
Oyster Point Pharma, Inc.
Oyster Point has launched a patient support program called TEAMTyrvaya™TYRVAYA is the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease PRINCETON,...
Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray is Now Available at U.S. Regional Wholesalers for Distribution to Pharmacies for the Treatment of the Signs and Symptoms of Dry Eye Disease
November 03, 2021 16:05 ET
|
Oyster Point Pharma, Inc.
TYRVAYA is the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease TYRVAYA is designed to activate the trigeminal parasympathetic pathway resulting in...
Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021
November 02, 2021 16:45 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma to Report Third Quarter 2021 Financial Results on November 4, 2021
October 28, 2021 07:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2021 17:24 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Reports Second Quarter 2021 Financial Results and Recent Business Highlights
August 05, 2021 16:02 ET
|
Oyster Point Pharma, Inc.
PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 2021Initiated Hiring of U.S. Sales Representatives in July, with a Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in...
Oyster Point Pharma Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize OC-01 and OC-02 in Greater China
August 05, 2021 16:01 ET
|
Oyster Point Pharma, Inc.
Ji Xing Pharmaceuticals to develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for patients with dry eye disease in Greater ChinaOyster Point Pharma will receive a...